Key result
Atrial natriuretic peptide significantly decreased lung fibrotic area and infiltration of inflammatory cells in mice with bleomycin-induced pulmonary fibrosis.
Why the study?
Does ANP prevent lung fibrosis and inflammation in a mouse model of bleomycin-induced pulmonary fibrosis?
Does ANP prevent lung fibrosis and inflammation in a mouse model of bleomycin-induced pulmonary fibrosis?
ANP exerts protective anti-fibrotic and anti-inflammatory effects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice.
Answers are grounded in this paper and cite their sources.
ANP may warrant exploration as a fibrosis therapy; animal data leave open human translation and should not yet change practice.
BACKGROUND: Pulmonary fibrosis is a life-threatening disease characterized by progressive dyspnea and worsening pulmonary function. Atrial natriuretic peptide (ANP), a heart-derived secretory peptide used clinically in Japan for the treatment of acute heart failure, exerts a wide range of protective effects on various organs, including the heart, blood vessels, kidneys, and lungs. Its therapeutic properties are characterized by anti-inflammatory and anti-fibrotic activities mediated by the guanylyl cyclase-A (GC-A) receptor. We hypothesized that ANP would have anti-fibrotic and anti-inflammatory effects on bleomycin (BLM)-induced pulmonary fibrosis in mice. METHODS: Mice were divided into three groups: normal control, BLM with vehicle, and BLM with ANP. ANP (0.5 μg/kg/min via osmotic-pump, subcutaneously) or vehicle administration was started before BLM administration (1 mg/kg) and continued until the mice were sacrificed. At 7 or 21 days after BLM administration, fibrotic changes and infiltration of inflammatory cells in the lungs were assessed based on histological findings and analysis of bronchoalveolar lavage fluid. In addition, fibrosis and inflammation induced by BLM were evaluated in vascular endothelium-specific GC-A overexpressed mice. Finally, attenuation of transforming growth factor-β (TGF-β) signaling by ANP was studied using immortalized mouse endothelial cells stably expressing GC-A receptor. RESULTS: ANP significantly decreased lung fibrotic area and infiltration of inflammatory cells in lungs after BLM administration. Furthermore, similar effects of ANP were observed in vascular endothelium-specific GC-A overexpressed mice. In cultured mouse endothelial cells, ANP reduced phosphorylation of Smad2 after TGF-β stimulation. CONCLUSIONS: ANP exerts protective effects on BLM-induced pulmonary fibrosis via vascular endothelial cells.
No takes yet. Share an insight, caveat, or question.
Okamoto et al. (2017) studied Bleomycin-induced pulmonary fibrosis (n=60). Atrial natriuretic peptide (ANP) vs. Vehicle was evaluated on Lung fibrotic area (p=<0.05). Atrial natriuretic peptide significantly decreased lung fibrotic area and infiltration of inflammatory cells in mice with bleomycin-induced pulmonary fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: